SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

ECLIPSE 2 is one of three trials in Vir Biotechnology’s registrational ECLIPSE program for CHD, which was initiated in March 2025.

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

Staging TV programs and commercials how to plan and execute sets, props, and production facilities Smithsonian Libraries and Archives Object Details author Wade, Robert J 1907- Notes NMAH copy ...

New quantum computing system allows multiple users to run programs simultaneously using virtual machines.

WASHINGTON—The Trump administration is blocking funding for a swath of public-health programs run by the Centers for Disease Control and Prevention, the latest flashpoint in a push by the White ...

Examining Dabo Swinney's 'first 16-0 team' College Football Playoff prediction: Can Clemson run the table? Dabo Swinney has never had a confidence issue ...

Nowhere to hide Codeberg, a Berlin-based code hosting community, is struggling to cope with a deluge of AI bots that can now bypass previously effective defenses.… In a series of posts to the ...

Merkley introduced a bill to release all Epstein investigation files, saying anyone involved in abusing minors “should be held accountable.” ...